Probiotic therapy
This article was originally published in The Tan Sheet
Executive Summary
Lactobacillus "is safe and effective as a treatment for infectious diarrhea in children," according to meta-analysis published in April Pediatrics. Cornelius Van Niel, MD, University of Washington, et al., found a significant .7 day reduction in diarrhea duration among subjects who were given Lactobacillus compared with placebo, and a reduction in diarrhea frequency of 1.6 stools on second day of treatment with the probiotic. Researchers did not find the effect was modified by country of study or live versus killed Lactobacillus preparation. Meta-analysis included nine randomized, controlled trials from 1973 to 2000 examining children up to three years old. Van Niel et al. suggest additional research should include a large, randomized trial funded by a non-vested party, use of consistent measures of diarrhea intensity...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.